



## Arbutus Announces Conference Call to Provide a Corporate Update and Third Quarter 2017 Financial Results

October 31, 2017

VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, November 2, 2017 at 1:15 PM Pacific Time (4:15 PM Eastern Time) to discuss third quarter 2017 financial results and provide a corporate update.

### Speakers will include:

- Dr. Mark Murray, President and Chief Executive Officer
- Dr. Mike Sofia, Chief Scientific Officer
- Dr. Bill Symonds, Chief Development Officer
- Mr. Bruce Cousins, Executive Vice President and Chief Financial Officer

To access the conference call, a live webcast of the call can be accessed through the Investor section of Arbutus' website at [www.arbutusbio.com](http://www.arbutusbio.com). Or, alternatively, to access the conference call, please dial 1-914-495-8556 or 1-866-393-1607.

An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-404-537-3406 or 1-855-859-2056 and referencing conference ID 1177108.

### About Arbutus

Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit [www.arbutusbio.com](http://www.arbutusbio.com).

### Contact Information

#### Investors

Bruce Cousins  
Executive Vice President and Chief Financial Officer  
Phone: 604-419-3200  
Email: [bcousins@arbutusbio.com](mailto:bcousins@arbutusbio.com)

Tiffany Tolmie  
Manager, Investor Relations  
Phone: 604-419-3200  
Email: [ttolmie@arbutusbio.com](mailto:ttolmie@arbutusbio.com)

#### Media

David Schull  
Russo Partners  
Phone: 858-717-2310  
Email: [david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

Source: Arbutus Biopharma Corporation